Immune Design Corporation (Nasdaq: IMDZ)

https://www.immunedesign.com

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the two-pronged focus of Immune Design's ongoing immuno-oncology clinical programs, are the product of its two synergistic discovery platforms, ZVexTM and GLAASTM. Immune Design has offices in Seattle and South San Francisco. *

	Start	2016-03-07 existent
	Industry	cancer immunotherapy (immuno-oncology, I-O)

	Region	Seattle, WA
	Country	United States (USA)
	Street	1616 Eastlake Avenue East Suite 310
	City	98102 Seattle, WA
	Tel	+1-206-682-0645
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	USD
	Annual sales	9,510,000 (revenues, total (2015) 2015-12-31)
	Profit	-39,445,000 (2015-12-31)
	Cash	112,921,000 (2015-12-31)

		* Document for »About Section«:

		Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]